Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to $540000.0.

  • Akebia Therapeutics' Income from Continuing Operations rose 10269.47% to $540000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.9 million, marking a year-over-year increase of 6541.79%. This contributed to the annual value of -$69.4 million for FY2024, which is 3367.36% down from last year.
  • Per Akebia Therapeutics' latest filing, its Income from Continuing Operations stood at $540000.0 for Q3 2025, which was up 10269.47% from $247000.0 recorded in Q2 2025.
  • Akebia Therapeutics' Income from Continuing Operations' 5-year high stood at $29.0 million during Q2 2022, with a 5-year trough of -$84.3 million in Q2 2021.
  • Moreover, its 5-year median value for Income from Continuing Operations was -$18.0 million (2024), whereas its average is -$26.1 million.
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first soared by 13444.48% in 2022, then crashed by 381400.65% in 2024.
  • Akebia Therapeutics' Income from Continuing Operations (Quarter) stood at -$70.4 million in 2021, then skyrocketed by 90.76% to -$6.5 million in 2022, then skyrocketed by 109.44% to $614000.0 in 2023, then tumbled by 3814.01% to -$22.8 million in 2024, then soared by 102.37% to $540000.0 in 2025.
  • Its Income from Continuing Operations was $540000.0 in Q3 2025, compared to $247000.0 in Q2 2025 and $6.1 million in Q1 2025.